|Study: Immune-related gene may predispose to HPV-related cancer|
About 70% of an estimated 30,000 oropharyngeal cancer cases in the U.S. annually are attributed to HPV, the most common sexually transmitted infection in the U.S. Studies show that most patients with oropharyngeal squamous cell carcinoma (OPSCC) are ...
DrBicuspid.com - Fri, 24 Oct 2014 11:00
|Eli Lilly and's (LLY) CEO John Lechleiter on Q3 2014 Results - Earnings Call ...|
And here in the U.S., we submitted ramucirumab to the FDA as a treatment for second line non-small cell lung cancer. The FDA assigned a priority review and we anticipate FDA action before the end of this year. This could lead to a launch in early 2015.
Seeking Alpha (registration) - Thu, 23 Oct 2014 19:03
|Topoisomerase IIα in chromosome instability and personalized cancer therapy|
An earlier study performed an immunohistochemical analysis to evaluate the levels of BRG1 in primary non-small cell lung cancers and found that 30% of tumors had no detectable protein, suggesting BRG1 inactivation.99 Furthermore, loss of nuclear ...
Nature.com - Mon, 20 Oct 2014 03:20
|Lymphovascular invasion is significantly associated with biochemical relapse ...|
LVI in RP specimens might be associated with recurrence or progression of disease like urothelial carcinoma; however, the previous reports were likely to have small sample size, and other factors like extra prostatic extension, seminal vesicle invasion ...
Nature.com - Tue, 21 Oct 2014 03:16
|Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo (nivolumab ...|
... checkpoint inhibitor Opdivo (nivolumab)with three molecularly targeted oncology therapies (Zykadia (ceritinib), INC280 and EGF816) from Novartis NVS, +1.02% Novartis will conduct two Phase 1/2 studies focused on non-small cell lung cancer (NSCLC).
MarketWatch - Mon, 06 Oct 2014 05:05
|BMS Launches Cancer-Combo Collaborations with Novartis, MD Anderson|
Genetic Engineering & Biotechnology News - Mon, 06 Oct 2014 07:30
|Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel ...|
PipelineReview.com (press release) - Mon, 06 Oct 2014 06:52
|Bristol-Myers Squibb Company : Bristol-Myers Squibb Announces Collaboration ...|
The Wall Street Transcript - Mon, 06 Oct 2014 05:14
|Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's ...|
NASDAQ - Sun, 05 Oct 2014 22:15
|MD Anderson, BMS enter research collaboration in immuno-oncology focused ...|
Pharmaceutical Business Review - Tue, 07 Oct 2014 04:18
|NCI Awards $1.4 Million Grant to Develop Test for B-Cell NHLs|
Microscope Advanced Cell Diagnostics, Inc. (ACD) and Cleveland Clinic were jointly awarded a 2-year, $1.4 million grant from the National Cancer Institute (NCI) to develop and validate a diagnostic test to identify B-cell non-Hodgkin lymphomas (NHLs ...
OncLive - Tue, 14 Oct 2014 14:45
|VolitionRx Announces Prostate Cancer Collaboration with the University of ...|
Anaplastic prostate cancers are a clinically defined subset of prostate cancers that behave like small cell prostate carcinomas. Small cell prostate carcinoma is a morphological variant of prostate cancer that is rare at initial diagnosis but often ...
CNNMoney - Thu, 02 Oct 2014 05:00
|Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular ...|
In this study, HCC cell lines and a xenograft mouse model were used to determine the functions of MEF2C in vitro and in vivo, respectively. Specific plasmids and small interfering RNA were used to upregulate and downregulate MEF2C expression, ...
Nature.com - Mon, 20 Oct 2014 03:20